Close

BeiGene (BGNE) Doses First Patient in China Phase I Trial of BGB-A317

December 30, 2016 9:01 AM EST Send to a Friend
BeiGene, Ltd. (NASDAQ: BGNE) announced the dosing of the first patient in a Phase I clinical trial of BGB-A317, an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login